Cargando…
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients
INTRODUCTION: Single-nucleotide polymorphisms (SNPs) in codon 72 of the TP53 (also known as p53) gene (rs1042522) and in the promoter region of the MDM2 gene (SNP309; rs2279744) have been suggested to play roles in many cancers. We investigated whether these SNPs were associated with patient outcome...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1929098/ https://www.ncbi.nlm.nih.gov/pubmed/17537232 http://dx.doi.org/10.1186/bcr1682 |
_version_ | 1782134258738921472 |
---|---|
author | Toyama, Tatsuya Zhang, Zhenhuan Nishio, Mariko Hamaguchi, Maho Kondo, Naoto Iwase, Hirotaka Iwata, Hiroji Takahashi, Satoru Yamashita, Hiroko Fujii, Yoshitaka |
author_facet | Toyama, Tatsuya Zhang, Zhenhuan Nishio, Mariko Hamaguchi, Maho Kondo, Naoto Iwase, Hirotaka Iwata, Hiroji Takahashi, Satoru Yamashita, Hiroko Fujii, Yoshitaka |
author_sort | Toyama, Tatsuya |
collection | PubMed |
description | INTRODUCTION: Single-nucleotide polymorphisms (SNPs) in codon 72 of the TP53 (also known as p53) gene (rs1042522) and in the promoter region of the MDM2 gene (SNP309; rs2279744) have been suggested to play roles in many cancers. We investigated whether these SNPs were associated with patient outcome and the effect of adjuvant systemic therapy. METHODS: The genotypes of TP53 codon 72 and MDM2 SNP309 were defined among 557 primary Japanese breast cancer patients (median follow-up, 61.7 months). The effects of several variables on survival were tested by Cox's proportional hazards regression analysis. RESULTS: We showed that the Pro/Pro genotype of TP53 codon 72 was associated with poorer disease-free survival (DFS) than other genotypes by Kaplan-Meier analysis (P = 0.049) and multivariate Cox's proportional hazards regression analysis (P = 0.047, risk ratio of recurrence = 1.67), whereas MDM2 SNP309 status was not associated with DFS. The association of the Pro/Pro TP53 genotype with poorer DFS was especially significant in patients who received adjuvant chemotherapy (P = 0.009). In contrast, among the patients who had received adjuvant hormonal therapy or no adjuvant systemic therapy, TP53 codon 72 genotype was not associated with DFS. CONCLUSION: The Pro/Pro genotype of TP53 codon 72 appears to be an independent prognostic marker in breast cancer patients. |
format | Text |
id | pubmed-1929098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-19290982007-07-21 Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients Toyama, Tatsuya Zhang, Zhenhuan Nishio, Mariko Hamaguchi, Maho Kondo, Naoto Iwase, Hirotaka Iwata, Hiroji Takahashi, Satoru Yamashita, Hiroko Fujii, Yoshitaka Breast Cancer Res Research Article INTRODUCTION: Single-nucleotide polymorphisms (SNPs) in codon 72 of the TP53 (also known as p53) gene (rs1042522) and in the promoter region of the MDM2 gene (SNP309; rs2279744) have been suggested to play roles in many cancers. We investigated whether these SNPs were associated with patient outcome and the effect of adjuvant systemic therapy. METHODS: The genotypes of TP53 codon 72 and MDM2 SNP309 were defined among 557 primary Japanese breast cancer patients (median follow-up, 61.7 months). The effects of several variables on survival were tested by Cox's proportional hazards regression analysis. RESULTS: We showed that the Pro/Pro genotype of TP53 codon 72 was associated with poorer disease-free survival (DFS) than other genotypes by Kaplan-Meier analysis (P = 0.049) and multivariate Cox's proportional hazards regression analysis (P = 0.047, risk ratio of recurrence = 1.67), whereas MDM2 SNP309 status was not associated with DFS. The association of the Pro/Pro TP53 genotype with poorer DFS was especially significant in patients who received adjuvant chemotherapy (P = 0.009). In contrast, among the patients who had received adjuvant hormonal therapy or no adjuvant systemic therapy, TP53 codon 72 genotype was not associated with DFS. CONCLUSION: The Pro/Pro genotype of TP53 codon 72 appears to be an independent prognostic marker in breast cancer patients. BioMed Central 2007 2007-05-30 /pmc/articles/PMC1929098/ /pubmed/17537232 http://dx.doi.org/10.1186/bcr1682 Text en Copyright © 2007 Toyama et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Toyama, Tatsuya Zhang, Zhenhuan Nishio, Mariko Hamaguchi, Maho Kondo, Naoto Iwase, Hirotaka Iwata, Hiroji Takahashi, Satoru Yamashita, Hiroko Fujii, Yoshitaka Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients |
title | Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients |
title_full | Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients |
title_fullStr | Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients |
title_full_unstemmed | Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients |
title_short | Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients |
title_sort | association of tp53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1929098/ https://www.ncbi.nlm.nih.gov/pubmed/17537232 http://dx.doi.org/10.1186/bcr1682 |
work_keys_str_mv | AT toyamatatsuya associationoftp53codon72polymorphismandtheoutcomeofadjuvanttherapyinbreastcancerpatients AT zhangzhenhuan associationoftp53codon72polymorphismandtheoutcomeofadjuvanttherapyinbreastcancerpatients AT nishiomariko associationoftp53codon72polymorphismandtheoutcomeofadjuvanttherapyinbreastcancerpatients AT hamaguchimaho associationoftp53codon72polymorphismandtheoutcomeofadjuvanttherapyinbreastcancerpatients AT kondonaoto associationoftp53codon72polymorphismandtheoutcomeofadjuvanttherapyinbreastcancerpatients AT iwasehirotaka associationoftp53codon72polymorphismandtheoutcomeofadjuvanttherapyinbreastcancerpatients AT iwatahiroji associationoftp53codon72polymorphismandtheoutcomeofadjuvanttherapyinbreastcancerpatients AT takahashisatoru associationoftp53codon72polymorphismandtheoutcomeofadjuvanttherapyinbreastcancerpatients AT yamashitahiroko associationoftp53codon72polymorphismandtheoutcomeofadjuvanttherapyinbreastcancerpatients AT fujiiyoshitaka associationoftp53codon72polymorphismandtheoutcomeofadjuvanttherapyinbreastcancerpatients |